Business Context and Reporting Period
Company: The Chemours Company
Filing Type: Form 8-K (Current Report)
Date of Report: November 27, 2020
Event: Completion of a private offering of senior notes and amendments to existing debt indentures.
Key Financial Metrics and Capital Structure
- New Debt Issuance: $800,000,000 aggregate principal amount of 5.750% Senior Notes due 2028.
- Interest Terms: Semi-annual payments in arrears on May 15 and November 15, commencing May 15, 2021.
- Maturity Date: November 15, 2028.
- Debt Purpose: Net proceeds are intended to repurchase or redeem all outstanding 6.625% Senior Notes due 2023 (the "2023 Notes"), utilizing cash on hand as needed.
- Security Status: The new Notes are unsecured and unsubordinated obligations, ranking equally with existing unsecured indebtedness.
Material Changes and Debt Restructuring
The filing details a refinancing transaction designed to extend the maturity profile of the Company's debt and reduce interest costs.
- Refinancing Strategy: The Company is replacing the 6.625% Senior Notes due 2023 with the new 5.750% Senior Notes due 2028. This action extends the debt maturity by five years and lowers the coupon rate by 0.875 percentage points.
- 2023 Notes Amendments: The Company executed the Fifth Supplemental Indenture to amend the terms of the 2023 Notes. Key changes include shortening the minimum notice period for optional redemptions from 30 days to as little as one or two business days, depending on the redemption scenario.
- Consent Solicitation: Holders representing a majority of the 2023 Notes consented to the amendments, facilitating the refinancing process.
Outlook, Risks, and Covenants
- Redemption Rights: The Company may redeem the new Notes prior to November 15, 2023, at a "make-whole" premium. Between November 15, 2023, and maturity, redemption is permitted at specified prices. Up to 35% of the principal may be redeemed prior to November 15, 2023, using proceeds from equity offerings at 105.750% of principal.
- Change of Control: In the event of a Change of Control coupled with a rating downgrade, the Company must offer to repurchase the Notes at 101% of the principal amount plus accrued interest.
- Covenants: The Indenture includes limitations on creating liens on assets and restrictions on consolidation, merger, or asset sales, subject to standard exceptions.
- Liquidity: The transaction relies on the successful closing of the offering and the availability of cash on hand to fully retire the 2023 Notes.
Investor Verification Checklist
- Verify the final net proceeds from the $800 million offering after deducting underwriting fees and expenses.
- Confirm the exact amount of cash on hand utilized to bridge the gap between new proceeds and the total redemption price of the 2023 Notes.
- Review the specific redemption price schedule for the new Notes post-November 15, 2023, as referenced in the Indenture.
- Assess the impact of the reduced interest rate (from 6.625% to 5.750%) on future interest expense and EBITDA.
- Check for any remaining outstanding balance of the 2023 Notes if the tender offer did not result in 100% participation.